| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Miranda Grounds | Q63882655 |
| Vered Raz | Q87734521 | ||
| Raffaella Willmann | Q89746812 | ||
| Maaike van Putten | Q90733711 | ||
| Jessica C de Greef | Q90733715 | ||
| P2093 | author name string | Erin M Lloyd | |
| P2860 | cites work | Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD | Q21563357 |
| Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies | Q22001192 | ||
| Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy | Q24310537 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy | Q24621454 | ||
| Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice | Q24633931 | ||
| Gene targeting in mice: a review | Q27001077 | ||
| Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy | Q28084979 | ||
| The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development | Q28088277 | ||
| Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy | Q28144192 | ||
| Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E | Q28144858 | ||
| Defective membrane repair in dysferlin-deficient muscular dystrophy | Q28203095 | ||
| Oculopharyngeal muscular dystrophy: a polyalanine myopathy | Q28303935 | ||
| Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy | Q28315028 | ||
| X chromosome-linked muscular dystrophy (mdx) in the mouse | Q28589078 | ||
| Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting | Q29616145 | ||
| Human skeletal muscle xenograft as a new preclinical model for muscle disorders | Q33649287 | ||
| A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene | Q33756692 | ||
| Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy | Q33787898 | ||
| Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice | Q33838074 | ||
| ENU Mutagenesis in the Mouse | Q33964080 | ||
| Animal models for muscular dystrophy: valuable tools for the development of therapies | Q34045919 | ||
| Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres | Q34102486 | ||
| Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials | Q34152280 | ||
| A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy | Q34175938 | ||
| Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene | Q34319775 | ||
| Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice | Q34360151 | ||
| Oculopharyngeal muscular dystrophy as a paradigm for muscle aging | Q34449597 | ||
| Muscular dystrophy into the new millennium | Q34682745 | ||
| Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. | Q34699458 | ||
| Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse | Q34786048 | ||
| Technical approaches for mouse models of human disease | Q34990916 | ||
| Generation of embryonic stem cells and mice for duchenne research | Q34993910 | ||
| Emerging preclinical animal models for FSHD. | Q35582587 | ||
| A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. | Q52688621 | ||
| Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy. | Q53072086 | ||
| Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. | Q54127324 | ||
| Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy. | Q54979072 | ||
| Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment | Q57046296 | ||
| A long-term treatment with taurine prevents cardiac dysfunction in mdx mice | Q57821110 | ||
| Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B | Q57990899 | ||
| "Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic | Q58713728 | ||
| AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD | Q59350986 | ||
| Report on the workshop: Meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30–31 January 2017 | Q59876191 | ||
| Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy | Q60215160 | ||
| Generating mouse models for biomedical research: technological advances | Q61800727 | ||
| CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human gene | Q64088115 | ||
| Deacetylation Inhibition Reverses PABPN1-Dependent Muscle Wasting | Q64236077 | ||
| Diagnostics of short tandem repeat expansion variants using massively parallel sequencing and componential tools. | Q64895891 | ||
| The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation | Q70054992 | ||
| Spontaneous myopathy in the SJL/J mouse: pathology and strength loss | Q71974084 | ||
| Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy | Q73677664 | ||
| Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer | Q82892069 | ||
| Muscular dystrophies | Q86291937 | ||
| A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping | Q90465691 | ||
| Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency | Q90497140 | ||
| The use of genetically humanized animal models for personalized medicine approaches | Q90573153 | ||
| 229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017 | Q90589536 | ||
| A comparison of the bone and growth phenotype of mdx, mdx:Cmah-/- and mdx:Utrn +/- murine models with the C57BL/10 wild-type mouse | Q91385646 | ||
| Various effects of AAV9-mediated βARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and δ-sarcoglycan-deficient (Sgcd-/-) mice | Q91722370 | ||
| Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy | Q91888065 | ||
| Therapeutic developments for Duchenne muscular dystrophy | Q92419746 | ||
| Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F | Q92727048 | ||
| Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy | Q92748970 | ||
| Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice | Q92774521 | ||
| Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice. | Q47164258 | ||
| Increased non-HDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B. | Q47413106 | ||
| New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin | Q48123207 | ||
| Muscular dystrophy in the mouse caused by an allele at the dy-locus | Q48933782 | ||
| A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system | Q49076566 | ||
| A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy | Q50133251 | ||
| Lipid accumulation in dysferlin-deficient muscles. | Q50475338 | ||
| Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. | Q50489087 | ||
| Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology. | Q50962265 | ||
| Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. | Q51089580 | ||
| 4th Annual Dysferlin Conference 11-14 September 2010, Washington, USA. | Q51159136 | ||
| Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. | Q51535716 | ||
| Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. | Q52527217 | ||
| Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. | Q52527453 | ||
| Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. | Q52539688 | ||
| Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice | Q35583176 | ||
| Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice | Q35779807 | ||
| Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury | Q35865366 | ||
| PABPN1-Dependent mRNA Processing Induces Muscle Wasting. | Q36010483 | ||
| Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice | Q36254595 | ||
| Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice | Q36276730 | ||
| Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin | Q36290630 | ||
| Genetic and epigenetic contributors to FSHD. | Q36359473 | ||
| Effect of genetic background on the dystrophic phenotype in mdx mice. | Q36402584 | ||
| The effects of high-fat feeding on physical function and skeletal muscle extracellular matrix | Q36526470 | ||
| Two-tiered hypotheses for Duchenne muscular dystrophy. | Q37104774 | ||
| Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics | Q37256163 | ||
| A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging | Q37298886 | ||
| Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models | Q37384623 | ||
| Mammalian animal models for Duchenne muscular dystrophy | Q37393140 | ||
| Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | Q37396962 | ||
| Influence of genetic background on genetically engineered mouse phenotypes | Q37407922 | ||
| Dysferlin and myoferlin regulate transverse tubule formation and glycerol sensitivity. | Q37415471 | ||
| Overview: generation of gene knockout mice | Q37435347 | ||
| Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B. | Q37462782 | ||
| 212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015. | Q37555754 | ||
| Dystrophia Muscularis: A HEREDITARY PRIMARY MYOPATHY IN THE HOUSE MOUSE. | Q37614861 | ||
| Oxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies. | Q38075201 | ||
| Muscular dystrophy in dysferlin-deficient mouse models | Q38087717 | ||
| Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy | Q38318433 | ||
| Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F | Q38630255 | ||
| Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment | Q38649036 | ||
| Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts. | Q38658555 | ||
| Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy | Q39697142 | ||
| Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in gamma-sarcoglycan-deficient mice | Q40667755 | ||
| Disruption of the lama2 gene in embryonic stem cells: laminin alpha 2 is necessary for sustenance of mature muscle cells | Q41032544 | ||
| Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy | Q41479197 | ||
| Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy | Q41527279 | ||
| Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model | Q41701355 | ||
| A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination | Q42435194 | ||
| Identification of a novel mutant transcript of laminin α2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice | Q42482053 | ||
| Differential expression of dystrophin isoforms in strains of mdx mice with different mutations | Q42640377 | ||
| Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy | Q42950227 | ||
| Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy | Q46582613 | ||
| Genetic background influences muscular dystrophy. | Q46637882 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P577 | publication date | 2020-02-21 | |
| P1433 | published in | Disease Models & Mechanisms | Q1524006 |
| P1476 | title | Mouse models for muscular dystrophies: an overview | |
| P478 | volume | 13 |
Search more.